ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Session » Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

Date: Tuesday, November 12, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

Abstract Number: 2128
Anti–MDA5 Antibody Positive Dermatomyositis Is Not Always Associated with Recalcitrant Lung Disease or Mortality
Abstract Number: 2129
Thyroperoxidase Antibodies in Patients with Positive ANA
Abstract Number: 2130
Enrichment of IL-17-producing CD4+ T Cells in Synovial Fluid from Patients with Arthritis After anti-CTLA-4 and anti-PD-1 Combination Therapy
Abstract Number: 2131
Rituximab Safety and Persistence in Patients with Systemic Autoimmune Diseases
Abstract Number: 2132
Complement Component 3 as Biomarker of Cardiometabolic Risk in Rheumatic Diseases: Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Systemic Lupus Erythematosus
Abstract Number: 2133
Acute Myocardial Infarction in Rheumatoid Arthritis, Gout, and Osteoarthritis: A Retrospective Study Using the National Inpatient Sample from 2002-2016
Abstract Number: 2134
Extracellular Adenosine Increases IL-6 Production by Aging Tenocytes and May Contribute to the Age-related Pattern of Polymyalgia Rheumatica
Abstract Number: 2135
Therapeutic Strategies and Survival in Patients with Interstitial Pneumonia with Autoimmune Features
Abstract Number: 2136
Cardiovascular Risk Evaluation in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Preliminary Results from the “Cardiovascular Obesity and Rheumatic DISease (CORDIS)” Study Group of the Italian Society of Rheumatology
Abstract Number: 2137
Overall Survival in Patients with PD-1 Inhibitor-related Inflammatory Arthritis and Metastatic Melanoma
Abstract Number: 2138
Rheumatic Immune-related Adverse Effects from Checkpoint Inhibitor Immunotherapy in Patients with Solid Tumors in a Latin American Population
Abstract Number: 2139
Rheumatic Immune-Related Adverse Events Associated with Treatment with Immune Checkpoint Inhibitors: A Multicenter Study of 38 Cases
Abstract Number: 2140
Preexisting Autoimmune Disease and Rheumatic Immune-Related Adverse Events Associated with Cancer Immunotherapy: A Case Series from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)
Abstract Number: 2141
Rituximab Therapy for Interstitial Pneumonia with Autoimmune Features (IPAF): A Case Series of Nineteen Patients
Abstract Number: 2142
Frailty in Systemic Rheumatic Diseases: A Systematic Review
Abstract Number: 2143
Neuromyelitis Optica Overlaps Frequently with Systemic Rheumatic Diseases in African-Americans: Experience at a Large US Academic Medical Center
Abstract Number: 2144
Musculoskeletal Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy: Single Center Experience
Abstract Number: 2145
Long-term Safety of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis: Incidence of Severe Infections Through 3 Years (148 Weeks) from 2 Phase 3 Trials
Abstract Number: 2146
Complications of Immune Checkpoint Inhibitor Therapy in Patients with and Without Pre-existing Rheumatologic Disease
Abstract Number: 2147
Musculoskeletal Ultrasound Enhances the Evaluation of Checkpoint Inhibitor Associated Musculoskeletal Immune Related Adverse Events
Abstract Number: 2148
Muscle Involvement Revealed by 18F-PET-CT in Polymyalgia Rheumatica
Abstract Number: 2149
Principal Components Analysis as a Tool to Identify Lesional Skin Patterns in Cutaneous Lupus Erythematosus
Abstract Number: 2150
Frequency of Polyautoimmunity in a Tertiary Hospital
Abstract Number: 2151
Patient Reported Outcomes and Factors Predicting Clinical Disease Activity in Patients with Immune-Checkpoint Inhibitor Inflammatory Arthritis
Abstract Number: 2152
Safety of Immune Checkpoint Inhibitors in Patients Treated for Cancer with Pre-existing Autoimmune Diseases
Abstract Number: 2153
Ocular Scleral Pathology and Relationship with Autoimmune Diseases: Study of 101 Patients from a Single Universitary Centre
Abstract Number: 2154
Role of Insulin Resistance and Inflammation on Resting Energy Expenditure in Patients with Rheumatoid Arthritis
Abstract Number: 2155
The Spectrum of Interstitial Lung Disease Associated with Autoimmune Diseases: Data of a 3-Year-Prospective Study from a Referral Center of Lung Transplantation
Abstract Number: 2156
Expanding the Phenotypic and Genotypic Spectrum in Yao Syndrome
Abstract Number: 2157
Checkpoint Inhibitor-Associated Arthritis: Phenotype, Steroid Dose, Serology and Survival
Abstract Number: 2158
Rheumatic Immune Related Adverse Events Associated with Cancer Immunotherapy: A Nationwide Multi-centre Canadian Cohort from the Canadian Research Group of Rheumatology in Immuno-oncology (CanRIO)
Abstract Number: 2159
Pachymeningitis in Rheumatic Disease

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.